Analytical Data
-
Gene name
CCDC41
- Application
-
Alternative Names
Coiled-coil domain-containing protein 41Renal carcinoma antigen NY-REN-58
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y592
-
Expression Region
1-568aa
-
Molecular Weight
83.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCDC41 (Coiled-Coil Domain Containing 41) is a protein that has gained increasing attention in recent years due to its potential role in cellular processes and disease mechanisms. Initial studies suggested that CCDC41 is involved in cellular responses to stress, particularly in relation to DNA damage repair and maintenance of genomic stability. Its coiled-coil domain indicates a structural element that may facilitate protein-protein interactions, hinting at a possible role in organizing intracellular signaling complexes. Investigations have indicated that mutations or dysregulation of CCDC41 expression may link it to various pathologies, including cancer and neurodegenerative disorders. Understanding the structure-function relationship of CCDC41, as well as its molecular interactions, could provide valuable insights into its biological functions and potential therapeutic targets. Moreover, the recombinant expression of CCDC41 provides an opportunity to analyze its functional properties in vitro, helping to elucidate the mechanistic pathways it influences. As research progresses, CCDC41 is increasingly viewed as a significant player in complex cellular mechanisms, warranting further exploration of its roles in health and disease. Overall, the investigation of CCDC41 and its recombinant protein forms holds promise for advancing our understanding of key biological processes and developing novel therapeutic strategies.
